Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis

被引:2
作者
Qin, Xueying [1 ,2 ]
Liu, Jingjing [1 ,2 ]
机构
[1] Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou 225001, Peoples R China
[2] Key Lab Syndrome Differentiat & Treatment Gastr Ca, Yangzhou 225001, Peoples R China
基金
中国国家自然科学基金;
关键词
Artificial nanoparticles; Nature biomaterials; Bionic nanoparticles; Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatohepatitis; FATTY LIVER-DISEASE; MESENCHYMAL STEM-CELLS; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; CANCER-DIAGNOSIS; NANOPARTICLES; MODEL; INFLAMMATION; PROGRESSION; LIPOSOMES;
D O I
10.1016/j.actbio.2024.06.014
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive phase of metabolic dysfunction- associated steatotic liver disease (MASLD) that develops into irreversible liver cirrhosis and hepatocellular carcinoma, ultimately necessitating liver transplantation as the sole life-saving option. However, given the drawbacks of liver transplantation, including invasiveness, chronic immunosuppression, and a lack of donor livers, prompt diagnosis and effective treatment are indispensable. Due to the limitations of liver biopsy and conventional imaging modalities in diagnosing MASH, as well as the potential hazards associated with liver-protecting medicines, numerous nanoformulations have been created for MASH theranostics. Particularly, there has been significant study interest in artificial nanoparticles, natural biomaterials, and bionic nanoparticles that exhibit exceptional biocompatibility and bioavailability. In this review, we summarized extracellular vesicles (EVs)-based omics analysis and Fe3O4 3 O 4-based functional magnetic nanoparticles as magnetic resonance imaging (MRI) contrast agents for MASH diagnosis. Additionally, artificial nanoparticles such as organic and inorganic nanoparticles, as well as natural biomaterials such as cells and cell-derived EVs and bionic nanoparticles including cell membrane-coated nanoparticles, have also been reported for MASH treatment owing to their specific targeting and superior therapeutic effect. This review has the potential to stimulate advancements in nanoformulation fabrication techniques. By exploring their compatibility with cell biology, it could lead to the creation of innovative material systems for efficient theragnostic uses for MASH. Statement of significance People with metabolic dysfunction-associated steatohepatitis (MASH) will progress to fibrosis, cirrhosis, or even liver cancer. It is imperative to establish effective theragnostic techniques to stop MASH from progressing into a lethal condition. In our review, we summarize the advancement of artificial, natural, and bionic nanoparticles applied in MASH theragnosis. Furthermore, the issues that need to be resolved for these cutting-edge techniques are summarized to realize a more significant clinical impact. We forecast the key fields that will advance further as nanotechnology and MASH research progress. Generally, our discovery has significant implications for the advancement of nanoformulation fabrication techniques, and their potential to be compatible with cell biology could lead to the creation of innovative materials systems for effective MASH theragnostic. (c) 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:37 / 53
页数:17
相关论文
共 125 条
[1]   Imaging biomarkers of NAFLD, NASH, and fibrosis [J].
Ajmera, Veeral ;
Loomba, Rohit .
MOLECULAR METABOLISM, 2020, 50
[2]   Innate Immunity and Inflammation in NAFLD/NASH [J].
Arrese, Marco ;
Cabrera, Daniel ;
Kalergis, Alexis M. ;
Feldstein, Ariel E. .
DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) :1294-1303
[3]   The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[4]   A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer [J].
Asgharpour, Amon ;
Cazanave, Sophie C. ;
Pacana, Tommy ;
Seneshaw, Mulugeta ;
Vincent, Robert ;
Banini, Bubu A. ;
Kumar, Divya Prasanna ;
Daita, Kalyani ;
Min, Hae-Ki ;
Mirshahi, Faridoddin ;
Bedossa, Pierre ;
Sun, Xiaochen ;
Hoshida, Yujin ;
Koduru, Srinivas V. ;
Contaifer, Daniel, Jr. ;
Warncke, Osinska ;
Wijesinghe, Dayanjan S. ;
Sanyal, Arun J. .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :579-588
[5]   Applications of nanoparticles for diagnosis and therapy of cancer [J].
Baetke, S. C. ;
Lammers, T. ;
Kiessling, F. .
BRITISH JOURNAL OF RADIOLOGY, 2015, 88 (1054)
[6]   Role of zinc oxide nanoparticles in alleviating hepatic fibrosis and nephrotoxicity induced by thioacetamide in rats [J].
Bashandy, Samir A. E. ;
Alaamer, Abdulaziz ;
Moussa, Sherif A. Abdelmottaleb ;
Omara, Enayat A. .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2018, 96 (04) :337-344
[7]   Cationized Ferritin as a Magnetic Resonance Imaging Probe to Detect Microstructural Changes in a Rat Model of Non-Alcoholic Steatohepatitis [J].
Beeman, Scott C. ;
Mandarino, Lawrence J. ;
Georges, Joseph F. ;
Bennett, Kevin M. .
MAGNETIC RESONANCE IN MEDICINE, 2013, 70 (06) :1728-1738
[8]   PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans [J].
Bezy, Olivier ;
Tran, Thien T. ;
Pihlajamaki, Jussi ;
Suzuki, Ryo ;
Emanuelli, Brice ;
Winnay, Jonathan ;
Mori, Marcelo A. ;
Haas, Joel ;
Biddinger, Sudha B. ;
Leitges, Michael ;
Goldfine, Allison B. ;
Patti, Mary Elizabeth ;
King, George L. ;
Kahn, C. Ronald .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (06) :2504-2517
[9]   Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice [J].
Bi, Youkun ;
Guo, Xuejun ;
Zhang, Mengqi ;
Zhu, Keqi ;
Shi, Chentao ;
Fan, Baoqi ;
Wu, Yanyun ;
Yang, Zhiguang ;
Ji, Guangju .
STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
[10]   Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease [J].
Boyer-Diaz, Zoe ;
Aristu-Zabalza, Peio ;
Andres-Rozas, Maria ;
Robert, Claude ;
Ortega-Ribera, Marti ;
Fernandez-Iglesias, Anabel ;
Broqua, Pierre ;
Junien, Jean-Louis ;
Wettstein, Guillaume ;
Bosch, Jaime ;
Gracia-Sancho, Jordi .
JOURNAL OF HEPATOLOGY, 2021, 74 (05) :1188-1199